Please login to the form below

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for patients with hyperkalaemia,” she added.
Vifor wins European approval for Veltassa

European Commission approves the drug to treat hyperkalaemia. The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening condition which can cause ... The European
FDA turns down AZ's ZS-9 once again on manufacturing issues

The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

for the treatment of hyperkalaemia.
Deal Watch November 2015

Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
Pharma deals during October 2013

Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Consultant: competitive salary

Vice President: Competitive Salary Offered

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Subscribe to our email news alerts

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...